We recently published a list of the 13 Most Undervalued Blue Chip Stocks To Buy According To Analysts. In this article, we ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

EMD Serono Inc., Merck KGaA’s North American drug development business ... stringent in managing our portfolio,” the ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

Last week, students and family members from Red Fox Community School participated in their annual Mountain Day hike at Merck ...

The event will pave the way for new commitments from First Ladies, ministers, and the Merck Foundation team to create more ...

PHILADELPHIA (WPVI) -- The American Red Cross continues to amplify the critical need for blood and platelet donors. Only 3 out of every 100 Americans have donated blood or platelets. With the supply ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

We retain conviction as Merck has started to transition from prioritizing its Keytruda franchise to building a more diversified business, with a focus on the Gardasil vaccine, pneumococcal vaccine ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in this pharmaceutical giant's success is its Keytruda immunotherapy drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...